An exploratory analysis of myelofibrosis (MF) patient subgroups by baseline hemoglobin levels in the gecacitinib phase 3 trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive ...
Pelabresib plus Jakafi showed superior spleen volume reduction and symptom improvement compared to Jakafi alone in myelofibrosis patients. The combination therapy resulted in fewer red blood cell ...
(a)-(d): The bone marrow biopsy shows mild hypercellularity (a, H&E 200×) and mild to moderate fibrosis (b, Reticulin stain, 200×). CD79a (c, 200×) and CD3 (d, 200×) immunostains highlight lymphoid ...
BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive ...
Typically, bone marrow research relies heavily on animal models and oversimplified cell cultures in the laboratory. Now, researchers from the Department of Biomedicine at the University of Basel and ...
Galecto is giving potential buyers and investors more data to chew over. Three months into a review of strategic alternatives, the biotech has posted topline results from a phase 2a clinical trial of ...
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results